Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
Executive Summary
CDER Director Woodcock grants accelerated approval after FDA Commissioner Califf refuses to overturn her finding that the drug's effect on dystrophin is reasonably likely to predict clinical benefit in Duchenne muscular dystrophy.
You may also be interested in...
Potential For Califf’s Second Term As US FDA Commissioner Surprises, Excites Stakeholders
Many supporters believe Robert Califf checks all the boxes, but if nominated he would also face many familiar confirmation challenges.
Potential For Califf’s Second US FDA Commissioner Term Surprises, Excites Stakeholders
Many supporters believe Robert Califf checks all the boxes, but if nominated he would also face many familiar confirmation challenges.
Changing Of The Guard At US FDA Continues With Unger Retirement
One of the US FDA’s most prominent review managers is retiring after nearly 25 years with the agency. Ellis Unger’s departure underscores a sense of transition in the leadership and mindset of the drug center.